Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
Episodes 46-60 of 183
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
NeuroFrontiersMetabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
Rethinking Migraine Care: Prioritizing Patient Needs and Restoring Function
On the Frontlines of MigraineRethinking Migraine Care: Prioritizing Patient Needs and Restoring Function
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
On the Frontlines of MigraineThe Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
Redefining Migraine Care: Early Diagnosis and Prevention Strategies
NeuroFrontiersRedefining Migraine Care: Early Diagnosis and Prevention Strategies
Challenging Migraine Stereotypes: Improving Patient Care Through Empathy and Insight
On the Frontlines of MigraineChallenging Migraine Stereotypes: Improving Patient Care Through Empathy and Insight
Data Equity in Action: Largest Real-World MS Analysis Confirms Fumarate Efficacy Across Racial Groups
NeuroFrontiersData Equity in Action: Largest Real-World MS Analysis Confirms Fumarate Efficacy Across Racial Groups
- advertisement
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
NeuroFrontiersIntermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
NeuroFrontiersEarly Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
NeuroFrontiersExploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
NeuroFrontiersQuantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
NeuroFrontiersCardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Managing Migraine: Inadequate Responses and Treatment Transitions
NeuroFrontiersManaging Migraine: Inadequate Responses and Treatment Transitions
- advertisement
Assessing Sex-Based Treatment Responses to Gepants In Migraine Management
On the Frontlines of MigraineAssessing Sex-Based Treatment Responses to Gepants In Migraine Management
American Headache Society Updates on Diagnosing and Treating Migraine
NeuroFrontiersAmerican Headache Society Updates on Diagnosing and Treating Migraine
Tuning the Brain: Personalized Anxiety Relief with Neurofeedback-Driven Headphones
NeuroFrontiersTuning the Brain: Personalized Anxiety Relief with Neurofeedback-Driven Headphones
